French biotech Transgene (Euronext: TNG) has appointed James Wentworth as chief business officer, with immediate effect.
Dr Wentworth, who will also join the executive management team at the virus-based immunotherapy specialist, will lead business, corporate development and partnering strategies.
Transgene, an early pioneer of cancer vaccines, is developing the individualized neoantigen product TG4050, in partnership with Japanese company NEC (TYO: 6701). The firm is hoping to lead in a new treatment area, the market for which analysts at Future Market Insights estimate could be worth $25 billion by 2033.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze